Increased concentrations of free light chain lambda in sera from chronic hemodialysis patients.
Serum levels of FLc were determined in 5 pre-HD CRF patients, 63 CRF patients receiving HD therapy, 15 CAPD and 40 healthy volunteers. The highest serum FLc concentration was observed in patients receiving HD. Concentrations of kappa- and lambda FLc were higher than normal in patients with CRF, and were about 4-fold and 1.8 fold greater than control values in HD patients, with a predominance of lambda chains. This HD-associated elevation of serum FLc strongly suggests a role for FLc in the etiology of light chain deposit disease and AL-amyloidosis. Lambda-FLc and beta 2-m exhibited similar patterns of change in the serum during the course of HD therapy. Further studies may reveal other pathological conditions other than CRF in which these polypeptides may play a role.
Wakasugi
K
K
Department of Internal Medicine, Tokyo Medical College at Hachioji.
Sasaki
M
M
Suzuki
M
M
Azuma
N
N
Nobuto
T
T
D002349:Carpal Tunnel Syndrome / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000097:blood*; D007146:Immunoglobulin lambda-Chains / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D008567:Membranes, Artificial; D012016:Reference Values; D006435:Renal Dialysis / Q000009:adverse effects*; D001613:beta 2-Microglobulin / Q000378:metabolism
D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D008567:Membranes, Artificial; D001613:beta 2-Microglobulin